Science is becoming better able to target the right genetic and biomolecular pathways with the right tools. More effective delivery modalities are being elucidated and scientists are experiencing success in a higher proportion of cases. Datamonitor’s report, Drugs Of Tomorrow 2002: Breast Cancer, presents an in-depth analysis into the pipeline products likely to drive the breast cancer market in the future, with an emphasis on the biotechnology emergence which is supplying the innovative drive. This Analysis predicts how: * Existing unmet needs will be satisfied by incremental improvements in pharmacotherapeutic regimens, brought about by the biotechnology emergence * Dramatically increased response rates will be achieved with co-therapies, acting synergistically with existing cytotoxic and hormonal protocols * Value sales will be sustained within the breast cancer market. From these analyses, breast cancer-specific forecasts are presented from 2002 to 2010.
